FDA Enhances Flexibility in Cell and Gene Therapy Regulations

On January 11, 2026, the U.S. Food and Drug Administration (FDA) announced a significant shift in its regulatory approach to chemistry, manufacturing, and control (CMC) requirements for cell and gene therapies (CGTs). This change aims to expedite product development and facilitate the approval process for therapies targeting serious or life-threatening conditions. FDA Commissioner Marty Makary emphasized the need for tailored regulatory flexibility, stating, “Regulatory flexibility must be tailored for cell and gene therapies.”

PharmaphorumFDA - Food and Drug Administration

The FDA's Center for Biologics Evaluation and Research (CBER) has approved nearly 50 CGTs over the past decade, reflecting the growing interest and innovation in this field. CGTs are complex biologic products often produced in small batches, requiring sophisticated manufacturing processes that can be time-sensitive. The FDA's new approach builds on its experience with these therapies, aiming to streamline the CMC requirements while maintaining rigorous quality standards.

FDA - Food and Drug AdministrationPharmaphorum

The FDA's revised framework introduces several flexibilities in the CMC requirements for CGTs. These include adjustments to manufacturing specifications during clinical testing, process validation, and commercial supply stages. The goal is to provide a structured framework that allows for greater regulatory leeway without compromising product safety, purity, or potency. This initiative follows a roundtable discussion held by the FDA, which brought together experts to address the challenges in advancing CGT development.

Pharmaphorum

The FDA's changes are expected to foster innovation and accelerate the availability of CGTs to patients. Vinay Prasad, CBER's Chief Medical and Scientific Officer, noted the "tremendous enthusiasm" among product developers, which has led to a surge in CGT submissions. The agency aims to remove barriers and misconceptions that hinder expedited product development, ensuring that sponsors understand the types of regulatory flexibility that may be acceptable.

FDA - Food and Drug Administration

While the FDA's new approach has been generally well-received, some stakeholders express concerns about the potential risks associated with increased flexibility. Critics argue that while innovation is essential, it should not come at the expense of rigorous safety and efficacy standards. The FDA has reassured the public that these changes will not undermine its commitment to ensuring the safety and effectiveness of CGTs.

FDA - Food and Drug Administration

The FDA has communicated its commitment to transparency regarding the new regulatory flexibilities. “It is vital that every sponsor, no matter the CBER reviewer team they engage with, understand what types of regulatory flexibility may be scientifically acceptable,” stated an FDA representative. This proactive communication aims to clarify the application of flexibilities that were previously implemented on a case-by-case basis.

FDA - Food and Drug Administration

The FDA is also working on new guidance for regenerative medicines and CGTs targeting serious conditions affecting small populations. This ongoing effort reflects the agency's dedication to adapting its regulatory framework to meet the evolving landscape of cell and gene therapies.

Pharmaphorum

• “Regulatory flexibility must be tailored for cell and gene therapies,” — Marty Makary, M.D., M.P.H., FDA Commissioner

FDA - Food and Drug Administration

• “There has been tremendous enthusiasm amongst product developers resulting in an explosive growth of cell and gene therapy submissions, many of which target serious or life-threatening conditions with an unmet medical need,” — Vinay Prasad, M.D., M.P.H., Chief Medical and Scientific Officer, CBER

FDA - Food and Drug Administration

• “It is vital that every sponsor, no matter the CBER reviewer team they engage with, understand what types of regulatory flexibility may be scientifically acceptable.” — FDA Representative

FDA - Food and Drug Administration